1/4
About Polydex

As far back as 1969, we have been engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry as well as the manufacture and marketing of biotechnology-based products for human pharmaceutical markets. Business is conducted through our wholly-owned subsidiaries, Dextran Products in Canada and Chemdex in the United States.

 

Common Shares

 

Shares Issued & Outstanding  -  3,432,978

An OTC Pink Foreign Issuer - POLXF

​Electronically Quoted with OTC Markets

Fiscal Year End  -  January 31st

Currently a SEC non-reporting issuer 

Recent News

 

September 15, 2021

Polydex Pharmaceuticals Ltd.

Issues Second Quarter Financial Results 

 

Financial Results Improved Over First Quarter despite Unprecedented Global Challenges